| Updated:
Astrazeneca knocked by US regulator drug verdict
UK pharma giant Astrazeneca was dealt a blow yesterday when US regulators knocked back its bid to gain accelerated approval for a new ovarian cancer drug.
Astrazeneca’s pipeline is under particular scrutiny after chief exec Pascal Soriot boasted of a bright and innovative future while fighting off a £69bn takeover bid from US rival Pfizer last month.
The firm must now submit further clinical data on the new drug.